Healthcare

HB 1157, the "Restore Trust in Public Health Messaging Act," requires Tennessee's Department of Health, local health departments, and state executive branch to ensure all public communications about FDA-regulated products (like medications) accurately reflect the FDA-approved or FDA-authorized labels. It prohibits promoting information that conflicts with these labels, including general product categories unless universally true or properly qualified. The law mandates an internal compliance review by July 2025, annual reporting to state officials starting in 2026, and a complaint process for violations with potential penalties. This directly affects state health agencies' public messaging about medical products, aiming to align communications with federal FDA standards.

SB 282, the "Individualized Investigational Treatment Act," creates a legal framework for patients with life-threatening or severely debilitating illnesses to access personalized medical treatments (like gene therapies or vaccines tailored to their genetic profile) when standard FDA-approved options have been exhausted. It directly affects eligible patients (who must meet specific criteria including physician attestation and written informed consent) and eligible facilities (those complying with federal human subjects protections). Key provisions require detailed written consent covering all treatment options, risks, and financial liability, while clarifying that insurers, health plans, and providers are **not obligated** to cover these treatments or related costs (TCA §§ 63-6-1304(a)-(d)). The law takes effect July 1, 2025, and explicitly states that heirs cannot be held liable for unpaid treatment debts if a patient dies during treatment (TCA § 63-6-1305).